With the first round of CMS price negotiations behind us, and the next list of targets to be released in February 2026, it’s clear that theorized implications from the Inflation Reduction Act are becoming realities for the life sciences industry. In this episode, Jen and Mindy are joined by Putnam Associates Partner, Scott Briggs, to explore how companies can navigate the new pricing pressures and negotiation frameworks while continuing to innovate and ensure patient access to critical therapies.

For more information about Putnam’s work in Value, Pricing and Access, visit their website: https://www.putassoc.com/our-expertise/value-pricing-access/

For more information about Vynamic’s work in Market Access, visit: https://vynamic.com/what-we-do/health-industry/life-sciences/market-access/

Podcast Tags: healthcare, life sciences, product launch, market access, drug pricing, life sciences trends

Panel – Scott Briggs, Mindy McGrath, Jen Burke

Research & Production – Scott Briggs, Mindy McGrath, Jen Burke

Recording & Editing – Mike Liberto, Rachel Skonecki

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.